NCT04343001

Coronavirus Response - Active Support for Hospitalised Covid-19 Patients

Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: London School of Hygiene and Tropical Medicine · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.

Detailed description

We will evaluate the effect of aspirin (150mg once daily), losartan (100mg once daily), and simvastatin (80mg once daily) in patients with COVID-19 infection. Eligible patients will be randomly allocated to one of eight study arms (aspirin only; losartan only; simvastatin only; aspirin and losartan; aspirin and simvastatin; losartan and simvastatin; aspirin, losartan and simvastatin; standard care only). Trial treatments are given in addition to the usual standard of care at the study hospital. Treatment will be started as soon as possible after randomisation and will continue until death, discharge or 28 days after randomisation, whichever occurs first.

Conditions

• Covid-19

Interventions

Type	Name	Description
DRUG	Aspirin	Aspirin 150mg
DRUG	Losartan	Losartan 100mg
DRUG	Simvastatin	Simvastatin 80mg

Timeline

• Start date: 2020-10-01
• Primary completion: 2021-04-01
• Completion: 2021-08-01
• First posted: 2020-04-13
• Last updated: 2020-11-19

Locations

2 sites across 2 countries: Nigeria, Pakistan